6hon MSN
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
Investors buying this biotech stock now will get its pipeline essentially for free.
A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...
The scientific case rests on updated results from PRESERVE-003, a Phase 3 trial run with partner OncoC4. The study tested Gotistobart as a monotherapy against the chemotherapy agent Docetaxel in ...
Merck and Moderna build a custom mRNA vaccine for each melanoma patient from tumor mutations. The strategy stumbles in cancers lacking enough targets ...
Berenberg lifted its BioNTech target to $140 while BMO cut to $105, as Phase 3 lung cancer data showed 18.5-month median survival. BioNTech's push to reinvent itself as an oncology player is drawing ...
A bombshell sworn declaration filed in federal court is raising new questions about the Biden-era COVID-19 vaccine mandate ...
Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and PfizerCAMBRIDGE, Mass., Sept.
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.
Wave Life Sciences Ltd. has appointed Dr. Monika Vnuk as chief business officer, creating a new executive leadership role as... Read More ...
Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO’s Presidential Symposium on October 24. Vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results